Stay ahead of the headlines

Mar 19, 2024·x.ai

On March 17, 2024, xAI announced the release of Grok-1, a 314 billion parameter Mixture-of-Experts language model, under the Apache 2.0 license. This groundbreaking model, distinguished by its vast parameter count and innovative architecture, was methodically trained from the ground up on an extensive corpus of text data without specific task optimization. Grok-1 stands out with 25% of its parameters being active for any given token, reflecting a strategic approach to model scaling and efficiency. The model, built using JAX and Rust, marks a significant advancement in machine learning, offering researchers and developers unparalleled access to one of the most powerful language processing tools available to date. Instructions for accessing and utilizing Grok-1's base model weights and architecture are provided on GitHub.

Mar 19, 2024·Fortune

During the Nvidia GTC Artificial Intelligence Conference in San Jose, California, Nvidia CEO Jensen Huang introduced the new Blackwell processor, designed to significantly enhance AI computing performance in both development and execution stages. Named after the pioneering mathematician David Blackwell, this chip contains 208 billion transistors and promises to revolutionize AI processing for major data center operators like Amazon, Microsoft, Google, and Oracle, with availability set for later this year. Highlighting Nvidia's leading position in AI technology and its market valuation exceeding $2 trillion, the Blackwell chip represents a leap in processing power and efficiency, incorporating innovative production techniques and offering improved networking capabilities. Huang's announcement reinforces Nvidia's central role in the ongoing AI-driven industrial transformation, emphasizing the company's strategy to democratize AI technology access across industries and government sectors.

Mar 18, 2024·Nature

Artificial Intelligence (AI) is now being used to address the slow and costly process of clinical trials, aiming to counteract the diminishing efficiency in drug development, known as Eroom's law. AI applications in trials include designing study protocols, enhancing patient recruitment, selecting eligibility criteria, and data analysis. Innovations such as predictive algorithms for trial success, automated patient recruitment systems, and digital twins to reduce control group sizes are notable examples. Furthermore, AI assists in optimizing trial parameters in real-time, identifying suitable patient candidates from databases, and employing wearables for data collection. These AI-driven methods not only expedite clinical research but also aim to broaden inclusivity in trial populations, potentially making drug development more efficient and inclusive.

Mar 15, 2024·Space.com

SpaceX's Starship, the world's largest and most powerful rocket to date, successfully reached orbital velocity on its historic third test flight from South Texas, despite neither the Starship vehicle nor its Super Heavy booster completing their intended splashdown. This test flight coincided with SpaceX's 22nd anniversary and marked a significant milestone, as previous flights had ended in explosions. Although the mission did not fully achieve its intended splashdown, SpaceX stated that key objectives were met, contributing to the development of the aerospace company's ambitious goals for space travel and the future transportation of humans to the Moon and Mars. The test also demonstrated advancements in SpaceX's launch capabilities, moving it closer to meeting NASA's needs for the Artemis 3 moon mission, though rapid progress is still required.

Mar 15, 2024·LinkedIn

John G. Singer, an executive at Blue Spoon Consulting, discusses the transformation required within the pharmaceutical industry beyond conventional marketing strategies. Pfizer and Amazon are highlighted as an example of direct distribution, emphasizing a novel approach to pharmaceutical distribution and market access innovation. This strategic shift aims to disrupt the traditional economic systems influenced by pharmacy benefit managers and employee benefits consultants, thereby reshaping how pharmaceuticals create market dynamics and customer experiences. Additionally, XO2Tech™ introduces an AI-Robot-Companion™ that marks a significant advancement in healthcare technology by integrating wearables, robotics, and AI to offer continuous healthcare monitoring and personalized care recommendations, also emphasizing the need for a holistic and patient-centric approach in healthcare technology development.

Mar 14, 2024·spectrum.ieee.org

The essence of Dina Genkina's article highlights a significant shift in the field of AI prompt engineering, particularly following the advent of ChatGPT in the fall of 2022. Initially, prompt engineering involved crafting queries to elicit the best responses from AI models, becoming a widespread practice among individuals and companies seeking to leverage AI for various applications. However, recent developments suggest that the future of prompt engineering lies in automating the process, allowing AI models to determine the most effective prompts themselves. Research by VMware on large language models (LLMs) reveals that autotuned prompts crafted by AI can outperform those devised by humans, indicating a move towards models that optimize their own prompts. This shift could render manual prompt optimization obsolete, as automated methods prove to be faster and more effective, generating unexpectedly successful and sometimes bizarre prompts. Furthermore, this approach has also been applied to image-generation algorithms, suggesting a broad potential impact across AI applications. Despite these advancements, the article suggests that the demand for human expertise in adapting AI to industry needs will persist, albeit under potentially evolving job titles and roles, reflecting the continuous and rapid evolution within the field of AI and prompt engineering.

Mar 14, 2024·DistilINFO HealthIT

"Revolutionizing Healthcare: Unveiling the Power of Artificial Intelligence," an article from DistilINFO Hospital IT, sheds light on the complex yet fascinating domain of AI in healthcare as presented by Dr. Jonathan Chen at the HIMSS AI in Healthcare Forum. The article encapsulates Chen's analysis of AI's potential to transform healthcare, balanced with a caution about the ethical challenges and the necessity for transparency in its application. By blending illustrative magic tricks with deep insights, Chen articulates the dual nature of AI as a tool of immense promise and peril, highlighting both its capacity to streamline healthcare operations and the ethical dilemmas it brings to the fore. The narrative stresses the importance of discernment in deploying AI, ensuring it augments rather than supplants human empathy and expertise in patient care. This piece offers a comprehensive overview of Chen's call for a nuanced approach to integrating AI in healthcare, aiming for a future where technology enhances the human aspects of care.

Mar 13, 2024·Business Insider

The closure of community hospitals across the United States has become increasingly common, notably impacting low-income communities and marking a significant shift in the landscape of healthcare access. These communities have seen at least 13 hospitals shut down or go bankrupt after their real estate was acquired by Medical Properties Trust (MPT) in a series of deals that shifted hospital ownership primarily to for-profit investors including private equity firms like Cerberus, Leonard Green, and Apollo. These deals often ended disastrously for the hospitals, imposing rent payments on properties they once owned and exacerbating financial struggles under the heavy debt from their for-profit owners. The situation highlights a broader issue of private equity profiting at the expense of essential healthcare infrastructure, with ongoing implications that threaten the viability of more hospitals and access to healthcare in underserved areas. The article raises concerns about the ethical and financial underpinnings of such investment strategies and calls into question their legality and impact on public health.

Mar 13, 2024·ScienceAlert

A novel therapy developed by Vaxxinity, codenamed UB-312, is showing promise in early clinical trials for treating Parkinson’s disease by targeting and reducing toxic clumps of alpha-synuclein protein in cerebrospinal fluid, a key factor believed to drive the disease's progression. This groundbreaking approach marks a significant advancement in the potential treatment and prevention of Parkinson's, offering hope for disease-modifying treatment. Early trial results suggest that UB-312 can lower levels of harmful protein aggregates, which may lead to improved motor function in patients. While the therapy is still under investigation and requires further testing to confirm its safety and efficacy, it represents a hopeful development for the nearly one million Americans currently diagnosed with Parkinson’s and those who will be diagnosed in the future.

Mar 13, 2024·TechCrunch

Elon Musk's artificial intelligence startup, xAI, is set to open source Grok, its chatbot that competes with ChatGPT, amid Musk's lawsuit against OpenAI for veering away from its open-source foundation. Grok, launched for X premium subscribers, features real-time information access and eschews political correctness. Musk's legal action challenges OpenAI's partnership with Microsoft, alleging a deviation from its original commitment to make AI technology widely available and accusing it of becoming a closed-source entity focused on profit. This move sparks broader discussions within the tech community about the value and future of open-source AI research, drawing mixed reactions from notable figures and commentators.

Mar 12, 2024·New York Magazine Intelligencer

In the article "The Self-Driving Car Bubble Has Popped" by John Herrman for Intelligencer, the focus is on Apple's discontinuation of its nearly decade-long endeavor to develop a self-driving car, known internally as Project Titan. Despite the recruitment of industry veterans and significant financial investment, the project was hindered by numerous challenges, including technological limitations and changing market dynamics, leading to its abrupt end. The broader context reveals a cooling enthusiasm for autonomous vehicles across the industry, marked by overoptimistic forecasts, high-profile failures, and a reevaluation of goals toward more achievable driving-assistance technologies. This shift underscores the complex realities facing the pursuit of fully autonomous vehicles, as companies grapple with both the technical and practical obstacles ahead.

Mar 12, 2024·Big Technology

In an article for Big Technology, David Kiferbaum, a former Google employee from 2015 to 2023, discusses the decline of Google’s once-celebrated open culture and its repercussions on the company's products. Kiferbaum shares his observations on how intense focus on politically correct language and the controversial firing of an employee for questioning diversity practices marked the beginning of the end for open discourse within the company. He reflects on the pre-2017 era when employees engaged freely in robust discussions at TGIF meetings, a practice that dwindled following leadership's response to internal and external controversies. This shift away from openness towards a more restrictive culture of communication, according to Kiferbaum, has visibly affected Google's product innovation and effectiveness, notably in instances like the Gemini project's failures and the stagnation of Google Assistant. The piece underscores the broader implications of a silenced workforce, suggesting that without a revival of its foundational open questioning ethos, Google is at risk of further setbacks, alienating both its employees and its user base.

Mar 12, 2024·Forbes

The Coalition for Health AI (CHAI), having amassed over 1,300 members, was launched with the aim of becoming the trusted source for AI best practices in health, emphasizing inclusivity and good governance reminiscent of historic "goo-goo" good government groups. Although partnered with notable stakeholders including Google and Microsoft, CHAI's ambitious goals raise questions about its ability to confront contentious AI uses in health care, such as secretive data collection practices, and whether it will ultimately prioritize technical standards over empowering patients to make their own health decisions. While the organization promises to revolutionize patient care through AI, its true commitment to transformative change versus technical fixes remains to be seen, mirroring the dual legacy of good governance advocates of the past.

Mar 9, 2024·Becker's Hospital Review

On March 7, Community Health Systems (CHS), based in Franklin, Tennessee, became the inaugural hospital system to form a partnership with and procure medications from Mark Cuban Cost Plus Drug Co., marking a significant step in addressing drug supply challenges and the escalating costs of pharmaceuticals. This collaboration aims to tackle issues such as pharmaceutical waste, drug shortages, and enhancing patient safety and medication error prevention by leveraging flexible drug ordering options, including offering medications in alternative vial sizes to minimize waste and dosage errors. Furthermore, Cost Plus Drugs is set to commence the production of epinephrine and norepinephrine in its new $11 million drug manufacturing facility in Dallas, with plans to extend its manufacturing to injectable drugs in shortage and pediatric oncology solutions. This partnership aligns with Cost Plus Drugs' ongoing efforts to integrate into the health system industry, offering a marketplace for essential medicines to hospitals, ASCs, clinics, and other healthcare facilities.

Mar 9, 2024·FierceBiotech

GE HealthCare, in collaboration with Vanderbilt University Medical Center (VUMC), has developed artificial intelligence (AI) models capable of predicting cancer patients' responses to immunotherapies with 70% to 80% accuracy by analyzing diverse sets of data from over 2,200 patients. These models utilize electronic medical records, including demographic, genomic, tumor, cellular, proteomic, and imaging data, to forecast both efficacy outcomes and the likelihood of severe side effects such as hepatitis, colitis, and pneumonitis. This advancement aims to move beyond the current trial-and-error methodologies and reliance on novel biomarkers, providing a more precise, data-driven approach to cancer treatment. GE HealthCare is exploring the commercialization of these AI technologies to enhance patient care and support biopharma drug development, contingent on regulatory approvals.

Mar 7, 2024·CNBC

Dexcom has received FDA clearance for its first over-the-counter continuous glucose monitor, Stelo, targeting patients with Type 2 diabetes who do not use insulin. This marks the first time a glucose biosensor will be available without a prescription, with sales starting in the summer of 2024. Stelo aims to improve diabetes management by tracking glucose levels in real-time, sending data wirelessly to a smartphone for more effective monitoring of the user's condition.

Mar 7, 2024·Deloitte

The "2024 Outlook for Health Care Planning for the Future of Health: Top trends for 2024" article by Tina Wheeler and Wendy Gerhardt from Deloitte LLP explores the ongoing challenges and innovations in the health care sector as it undergoes digital transformation and convergence. Amidst the digital revolution, health care executives grapple with which technologies to adopt under financial pressures, with the sector moving from fragmentation to systemic convergence. The outlook highlights the anticipated continuation of trends like mergers and acquisitions, digital transformation including generative AI, and increasing consumer empowerment, all within a framework of financial and operational pressures. Despite a general pessimism among health care executives regarding the sector's future, the piece suggests opportunities for significant innovation and reformation in response to these challenges. Key factors shaping the future include strategic mergers, digital integration, workforce management, outsourcing, and consumer affordability, with a collective emphasis on adapting to a rapidly evolving landscape for sustained success.

Mar 7, 2024·Forbes

Seth Joseph examines the controversial business practices of Epic Systems, a leading electronic health record (EHR) system provider, in his article for Forbes. He discusses how Epic's dominant market stance could potentially stifle healthcare innovation through various strategies, including limiting market visibility for competitors, imposing high third-party developer costs, and enforcing restrictive non-compete agreements. Joseph's analysis is based on conversations with industry insiders, highlighting concerns about Epic's approach to maintaining its market position, possibly at the expense of a more open and competitive landscape for healthcare technology innovation. The article raises questions about whether Epic's practices are merely competitive or cross the line into exclusionary, prompting a broader debate on the implications for the future of healthcare innovation.

Mar 7, 2024·Every

Jim Simons excelled in trading using algorithms; Composer allows easy creation and testing of such strategies for anyone. Claude 3, from Anthropic, praised for its human-like, creative AI, surpasses GPT-4 in nuance despite technical benchmark similarities. Its unique warmth and high token accuracy hint at groundbreaking AI advancements and synthetic data use, challenging conventional model evaluations and AI competition strategies.

Mar 7, 2024·Fortune

Mark Cuban's Cost Plus Drugs starts manufacturing its medications in Dallas, aiming for affordable pricing by eliminating middlemen.